GSK to Acquire Rapt for $2.2B Food Allergy Asset

GSK has agreed to acquire Rapt Therapeutics for $2.2 billion to expand its pipeline with Rapt’s ozureprubart (RPT904). Ozureprubart is a mid-phase anti-immunoglobulin E (IgE) monoclonal antibody being developed to protect against food allergens.

The therapy is designed for every-12-week dosing, aiming to reduce dosing frequency versus current two- or four-week regimens. GSK and Rapt position the asset as addressing unmet need in food allergy, including patients ineligible for existing therapy. The companies also expect ozureprubart to grow the treated patient population.